Cost to Medicare of Delayed Adalimumab Biosimilar Availability-Reference-Cited by-同舟云学术

Cost to Medicare of Delayed Adalimumab Biosimilar Availability

Published:2021-07-06 Issue:4 Volume:110 Page:1050-1056
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Lee ChangWon C.¹²,Najafzadeh Mehdi¹,Kesselheim Aaron S.¹,Sarpatwari Ameet¹

Affiliation:

1. Program on Regulation, Therapeutics, and Law (PORTAL) Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts USA

2. Harvard‐MIT Division of Health Sciences and Technology, Harvard Medical School Boston Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2322

Reference33 articles.

1. IQVIA.Medicine use and spending in the US: a review of 2018 and outlook to 2023 (2020). Accessed May 10 2021.

2. IQVIA.Biosimilars in the United States 2020–2024. (2020). Accessed May 16 2021.

3. Patient Protection and Affordable Care Act of 2010 Pub L No. 111‐148 124 Stat 119 (2010). Accessed May 10 2021.

4. Progress and Hurdles for Follow-on Biologics

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Clinical Benefit, Cost and Uptake of Biosimilars Versus Reference Biologics in Immune-Mediated Inflammatory Diseases in China;2024

2. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?;Value in Health;2023-12

3. Biosimilars in Dermatology Review;Journal of Psoriasis and Psoriatic Arthritis;2023-11-03

4. Consistency of Product Quality for SB5, an Adalimumab Biosimilar;BioDrugs;2023-01-31

5. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland;JAMA Network Open;2022-12-02